PAS
SRPT icon

Partnervest Advisory Services’s Sarepta Therapeutics SRPT Stock Holding History

Partnervest Advisory Services’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-100
Closed -$3K – 704
2014
Q2 		$3K Buy
+100
New +$3.16K ﹤0.01% 948

Other funds holding SRPT

CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Partnervest Advisory Services's SRPT Position: Q3 2014 in Review

Partnervest Advisory Services sold out of Sarepta Therapeutics (SRPT) in Q3 2014, closing a stake of 100 shares — an estimated $3K sold.

Partnervest Advisory Services first reported a position in SRPT in Q2 2014 and held it in 1 quarter. The position peaked at $3K in Q2 2014. 123 funds tracked by Wall St. Rank hold SRPT as of Q3 2014.

  • Partnervest Advisory Services reported no remaining Sarepta Therapeutics position as of Q3 2014 after selling out during the quarter.
  • Partnervest Advisory Services sold 100 Sarepta Therapeutics shares in Q3 2014, an estimated $3K.
  • Partnervest Advisory Services first reported a position in Sarepta Therapeutics in Q2 2014 and held it in 1 quarter.
  • Partnervest Advisory Services's Sarepta Therapeutics position peaked at $3K in Q2 2014.
  • 123 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2014.

Based on Partnervest Advisory Services's 13F filing for Q3 2014, filed 7 Nov 2014.